Flags

Financial distress

Oxford Biomedica

LSE:OXB · GB00BDFBVT43

BiotechnologySmall

360

Value48

Profit price90

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price39

Price/Sales70

EV / Gross Profit35

Price/Book11

Quality58

Returns on capital65

Return on Capital70

Cash Return on Capital73

Return on Equity51

Profit margins47

EBIT Margin36

Gross Profitability58

Cash backing63

Accruals56

Owner Earnings Margin69

Growth55

Sales growth75

Profit growth35

Profit Growth55

Long-Term EPS Growth14

Reinvestment84

Price momentum85

Safety34

Debt load28

Debt serviceability32

Refinancing63

Debt Payback1

Liquidity57

Sentiment43

Analyst ratings58

Expectations trend35

Opinion Changes50

Price Target Upside20

Market mood27

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Oxford Biomedica clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUK

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeLSE

Founded1996

Employees822

Websiteoxb.com

ISINGB00BDFBVT43

Last UpdateApr 2, 2026

Indices

FTSE 250 (United Kingdom)FTSE 350 (United Kingdom)FTSE All Shares (United Kingdom)

Themes

GeneticsStem Cell TherapyInfectious DiseasesOncologyBiotechnologyTherapeutics

Description

Oxford Biomedica plc is a gene and cell therapy company that focuses on proprietary therapeutic treatments and providing contract development and manufacturing organization (CDMO) services. The company specializes in the development and manufacturing…

Analysis

Middle-of-the-road

Oxford Biomedica plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Oxford Biomedica with its peers

Uniqure

NSQ:QURE

CountryNetherlands

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Galapagos

AEX:GLPG

CountryBelgium

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Enlivex Therapeutics

NAQ:ENLV

CountryIsrael

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Zealand Pharma

CPH:ZEAL

CountryDenmark

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Urogen Pharma

NMQ:URGN

CountryIsrael

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kamada

NSQ:KMDA

CountryIsrael

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →